Key Points

  • - Pfizer's stock price has surged recently due to an analyst upgrade and positive news about a new COVID-19 vaccine.
  • - However, a deeper analysis of the company's fundamentals is necessary for informed investment decisions.
  • - Pfizer's current quarter earnings are expected to decrease significantly compared to the previous year.
  • - The company is projected to deliver earnings growth for the current and next fiscal years, but these estimates have seen minor downward revisions.
  • - Pfizer's consensus sales estimate for the current quarter reflects a year-over-year decline, but growth is expected in the future.
  • - Pfizer has beaten consensus EPS estimates in the last four quarters but has only exceeded consensus revenue estimates once.
  • - The stock is currently trading at a discount to its peers, suggesting it may be undervalued.
  • - Long-term investors should consider Pfizer's growth potential and undervalued status, but should also conduct thorough research and consult with a financial advisor.

Pfizer Inc. (PFE) has captured headlines recently, with its stock price experiencing a surge on the back of an analyst upgrade and promising developments regarding a new COVID-19 vaccine. However, while these factors undoubtedly influence investor sentiment, a deeper dive into the company's fundamentals is crucial for making informed investment decisions.

Beyond the Buzz: Fundamentals Drive Long-Term Value

While media reports can influence short-term stock movements, fundamental factors ultimately determine a company's long-term value and, consequently, its stock price potential.

Pfizer's current quarter earnings are expected to be $0.53 per share, a significant 56.9% decrease year-over-year. Over the past month, the Consensus Estimate has also dipped slightly by 4.4%.

Looking at the broader picture, the company is still projected to deliver 20.7% earnings growth for the current fiscal year, and 25.1% growth for the next. However, these estimates have also seen minor downward revisions in the past 30 days.

While earnings are crucial, a company's ability to grow revenue is equally important. Pfizer's consensus sales estimate for the current quarter is $14.28 billion, reflecting a 21.9% year-over-year decline. However, the company is expected to return to growth territory in the current and next fiscal years, with projected increases of 2.6% and 3.6%, respectively.

Recent Performance and Valuation

Pfizer beat consensus EPS estimates in each of the last four quarters, while exceeding consensus revenue estimates only once over the same period.

In terms of valuation, Pfizer is currently trading at a discount to its peers. This suggests the stock could be potentially undervalued.

While the recent buzz surrounding Pfizer is noteworthy, a comprehensive analysis of its fundamentals, including earnings estimates, revenue growth, past performance, and valuation, paints a more nuanced picture. The stock may follow the broader market in the near term, but the company's growth potential and undervalued status warrant further consideration for long-term investors.

Pfizer's Ethics Under Fire

The pharmaceutical giant Pfizer finds itself embroiled in controversy over its alleged support for assisted suicide and euthanasia. Senator Marco Rubio of Florida has taken a stand against Pfizer's stance, particularly concerning the company's financial contributions to the "Dying with Dignity Canada" (DWDC) program. This revelation has raised concerns about Pfizer's position on assisted suicide, especially given DWDC's advocacy for lowering the age of eligibility for medically assisted death to as young as 12 years old.

The support extended by Pfizer to DWDC has prompted fears that the pharmaceutical company may be complicit in the premature ending of lives. Senator Rubio, alongside fellow Republican senators Ted Cruz, J.D. Vance, Josh Hawley, and Mike Braun, as well as congressmen Brad Wenstrup and Chris Smith, has addressed these concerns in a letter to Pfizer's CEO, Dr. Albert Bourla.

In their letter, the senators and congressmen highlight the contradiction between Pfizer's stated mission of "offering breakthroughs to change patients' lives" and its apparent support for medically assisted death. They argue that Pfizer's acceptance of millions of dollars in taxpayer funding for medical research and development necessitates transparency regarding the company's stance on assisted suicide.

While Pfizer's financial contributions to DWDC have sparked outrage and debate, the company's stock performance and financial outlook remain subjects of interest to investors and analysts. Despite the controversy surrounding its social and ethical positions, Pfizer continues to be evaluated based on fundamental factors such as earnings estimates, revenue growth projections, and valuation metrics.

It is vital to remember that the stock market is inherently volatile, and past performance is no guarantee of future results. Investors are strongly advised to conduct their own thorough research and due diligence before making any investment decisions. Consulting with a qualified financial advisor can also be beneficial in navigating the complexities of the stock market and making informed investment choices.


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $146B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE